The PennZone

  • Home
  • Business
  • Health
  • Education
  • Entertainment
  • Financial
  • Legal
  • Non-profit
  • Music

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • Pray the News Launches to Transform American Christians' Relationship with News
  • Penn Mutual Earns 2025 Great Place To Work Certification™
  • IRF Builders Forum Brings Global Leaders to Washington, D.C. to Advance Religious Freedom Through Cooperative Engagement
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • BeyondTrucks CEO Wins Gold Stevie® Award for Best Entrepreneur in Transportation
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.
4930 Bradshaw Court, San Diego, CA  92130

More on The PennZone
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • C8C.AI Launches Audio Compliance Engine to Streamline Ethical AI Audio Data at Scale
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
  • Winners Announced for Asia Pacific Business Awards 2024-2025

Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business, Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • $10 Million Acquisition of GXR World Sports Assets Energizes Global Launch of Sports.com Super App by Online Lottery-Sports Game Provider: Lottery.com
  • Shop American Made Goods: New Online Marketplace My American Goods Curates the Best of U.S. Made
  • Penn Mutual Earns 2025 Great Place To Work Certification™
  • Investor Spotlight: Cycurion, Inc. (N A S D A Q: CYCU) Secures $69M in Contracts Amid Surging Demand for AI-Powered Cybersecurity Solutions
  • $328 Million Global Stroke Rehab Market Opportunity Awaits AI Telehealth Leader Following Selection for NIH Funded Phase 3 Clinical Study: VSee Health
  • Ascent Solar Technologies Enters Collaborative Agreement Notice with NASA to Advance Development of Thin-Film PV Power Beaming Capabilities: ASTI
  • VoodooSoft Unveils SiriusLLM: The World's First ChatGPT-Like AI Malware Detection Engine
  • This Ain't Press. This Is Pressure — Star Command by RansomXX is Out Now
  • An Exclusive VIP Reception Honoring Vocal Prodigy Alliana Lili Yang's Remarkable Achievements and Magazine Cover Spotlight
  • Joyce Carol Oates Returns to Hard Case Crime With DOUBLE TROUBLE
  • New AI Academy Helps Therapists Embrace Tech Without Losing Their Humanity
  • Watch Out for Deed and Title Fraud Warns PA Association of Realtors®
  • IQSTEL Surges Toward $400M Run Rate with $101.5M in Revenue—Reinforces Billion-Dollar Vision Backed by Fintech, AI, and Cybersecurity
  • Alpha Modus Files 7th IP Action Against Rackspace Following $3M CEO Investment and Strategic Partnership Expansion
  • Mortgage Rates And Demand Are Stuck In A Holding Pattern
  • Coker Completes Acquisition of Healthcare Cost Solutions, a Leading Expert in Technology-Enabled Compliance Services
  • Keepy Uppy™ by Ollyball Wins Prestigious 2025 Influencer Award from Clamour & The Toy Association; Announces Fall 2025 Launch at Target Stores
  • K2 Integrity's U.S. and EMEA Teams Recognized in Chambers and Partners 2025 Guides
  • A rare chance to own a multi-family property in the heart of Bay Ridge
  • LA Laura Paris Drops Underground Girl Remixes

Popular on PennZone

  • AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names - 166
  • Garage Door Scam Alert: Superior Overhead Doors Warns Tulsa Homeowners About Red Flags - 104
  • A World First: The Global Naturism & Nudism Index Launched by NaturismRE™
  • Handel's Ice Cream Celebrates Grand opening Event in Rialto, California
  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident
  • Western Carolina Emergency Network Accepts 2025 ReadyCommunities Partnership/CCROA National Service Award for Collaboration to Augment Local Response
  • JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere
  • RNHA Named Official Community Partner of the First Annual CPAC Latino 2025
  • Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
  • Rediscovered Christopher Lee Recording 'Elenore' Re-Released to Mark 10th Anniversary of His Passing

Similar on PennZone

  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • INVESTIGATION ALERT: Berger Montague PC Investigates Aflac, Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: AFL)
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • BeyondTrucks CEO Wins Gold Stevie® Award for Best Entrepreneur in Transportation
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us